Experimental lung cancer drug MGY825 tested in early trial

NCT ID NCT05275868

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested an investigational drug called MGY825 in 41 adults with advanced non-small cell lung cancer that has specific genetic changes (NFE2L2/KEAP1/CUL3 mutations). The main goal was to check the drug's safety and find the right dose. The study was terminated early, so only limited safety and dosing information is available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MGY825
What this could lead to: If successful, this could point toward a new treatment option for a specific genetic subtype of advanced lung cancer.
What could go wrong: This was a very early, small Phase 1 trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering

New York, New York, 10017, United States
Memorial Sloan Kettering Onc. Dept

New York, New York, 10017, United States
NYU School of Medicine

New York, New York, 10015, United States
Novartis Investigative Site

Frankfurt am Main, Hesse, 60590, Germany
Novartis Investigative Site

Cologne, North Rhine-Westphalia, 50937, Germany
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Chuo Ku, Tokyo, 104 0045, Japan
Novartis Investigative Site

Seoul, 03080, South Korea
Novartis Investigative Site

Madrid, 28050, Spain
Novartis Investigative Site

Geneva, CH 1211, Switzerland
Novartis Investigative Site

Sankt Gallen, 9007, Switzerland
Uni Of TX MD Anderson Cancer Cntr

Houston, Texas, 77030, United States
Wash U School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.